LIGAND PHARMACEUTICALS INC

For the period ended Mar 31, 2026. Filed May 8, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 8, 2026

LGND$314.16+0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except par value)

	March 31, 2026	December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$115,077	$174,927
Short-term investments	664,328	558,594
Accounts receivable, net	53,383	59,601
Inventory	13,266	9,126
Short-term portion of financial royalty assets, net	12,151	22,792
Income taxes receivable	1,415	1,446
Other current assets	5,795	5,785
Total current assets	865,415	832,271
Intangible assets, net	217,341	225,438
Goodwill	101,541	101,541
Long-term portion of financial royalty assets, net	193,536	196,877
Noncurrent derivative assets	13,527	15,632
Equity method investments	31,515	46,500
Other investments	87,770	121,451
Deferred income taxes, net	8,473	8,345
Other assets	12,987	12,582
Total assets	$1,532,105	$1,560,637
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$5,264	$3,238
Accrued liabilities	31,845	31,453
Income taxes payable	1,893	1,239
Current contingent liabilities	277	287
Current operating lease liabilities	1,088	1,095
Other current liabilities	300	135
Total current liabilities	40,667	37,447
Long-term contingent liabilities	3,498	2,934
Long-term operating lease liabilities	3,993	4,204
2030 convertible senior notes, net	446,896	446,192
Deferred income taxes, net	22,614	36,019
Other long-term liabilities	17,115	16,629
Total liabilities	534,783	543,425
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Common stock, $0.001 par value; 60,000 shares authorized; 20,029 and 19,774 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	20	20
Additional paid-in capital	397,169	400,649
Accumulated other comprehensive income	5,390	8,455
Retained earnings	594,743	608,088
Total stockholders’ equity	997,322	1,017,212
Total liabilities and stockholders’ equity	$1,532,105	$1,560,637

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.